BT-001

About BioInvent International

BioInvent International is a clinical-stage biotechnology company with a mission to transform cancer treatment through the discovery and development of novel, targeted antibody therapies. The company's strategy is anchored in its proprietary F.I.R.S.T.™ and n-CoDeR® platforms, which enable the identification of biologically relevant targets and the generation of fully human antibodies directly from human tissue. BioInvent has advanced a pipeline of proprietary and partnered candidates, most notably the anti-FcγRIIB antibody BI-1206, positioning itself as a key player in the next wave of immuno-oncology innovation.

About transgene-sa

Transgene SA is a clinical-stage biotech focused on developing Individualized Neoantigen Therapeutic Vaccines (INTV) for early-stage solid tumors. The company's core asset is the myvac® platform, a viral vector system designed to elicit potent, tumor-specific T-cell responses. Under CEO Alessandro Riva, Transgene has undergone a strategic refocusing, prioritizing its lead program TG4050 in head and neck cancer, supported by a cash runway into early 2028. Recent Phase I data, presented as a preprint, suggests potential in preventing cancer relapse.

Therapeutic Areas

Other Solid Tumors Drugs